Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-01-16
2008-09-02
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S051000
Reexamination Certificate
active
07419966
ABSTRACT:
A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 3116282 (1963-12-01), Hunter
patent: 3553192 (1971-01-01), Gauri
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 4963662 (1990-10-01), Matthes et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 5011774 (1991-04-01), Farina et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5071983 (1991-12-01), Koszalka et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5233041 (1993-08-01), Bray et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5241069 (1993-08-01), Vince et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta et al.
patent: 5329008 (1994-07-01), Partridge et al.
patent: 5409906 (1995-04-01), Datema et al.
patent: 5432165 (1995-07-01), Adair et al.
patent: 5444063 (1995-08-01), Schinazi et al.
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5496935 (1996-03-01), Matthes et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5604209 (1997-02-01), Ubasawa et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6391859 (2002-05-01), Schinazi et al.
patent: 6680303 (2004-01-01), Schinazi et al.
patent: 2002/0198173 (2002-12-01), Schinazi et al.
patent: 1 620 047 (1970-03-01), None
patent: 0 217 580 (1987-04-01), None
patent: 0 285 884 (1988-10-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 375 329 (1990-06-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0409227 (1991-01-01), None
patent: 0 433 898 (1991-06-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: 0 519 464 (1992-12-01), None
patent: 0 526 253 (1993-02-01), None
patent: 0 206 497 (1994-07-01), None
patent: 0 337 713 (1995-10-01), None
patent: 0 515 157 (1997-09-01), None
patent: 7-109221 (1995-04-01), None
patent: 8901258 (1990-12-01), None
patent: WO 88/07532 (1988-10-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 90/12023 (1990-10-01), None
patent: WO 91/06554 (1991-05-01), None
patent: WO 91/09124 (1991-06-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 91/16333 (1991-10-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO91/19727 (1991-12-01), None
patent: WO 92/06102 (1992-04-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/10496 (1992-06-01), None
patent: WO 92/10497 (1992-06-01), None
patent: WO 92/14729 (1992-09-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 92/21676 (1992-12-01), None
patent: WO 93/23021 (1993-11-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO94/14456 (1994-07-01), None
patent: WO 94/14802 (1994-07-01), None
patent: WO 94/14831 (1994-07-01), None
patent: WO 94/27590 (1994-12-01), None
patent: WO94/27616 (1994-12-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO95/07287 (1995-03-01), None
patent: WO 95/18137 (1995-07-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 95/21183 (1995-08-01), None
patent: WO 96/22778 (1996-08-01), None
EPO Search Report for S.N. 96-902772, Jul. 26, 1999.
Lin et al., “Antiviral Activity of 2′,3′-Dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2′,3′-Dideoxy-§-L-cytidine (beta-L-ddC) Against Hepatitis B Virus and Human Immunodeficiency Virus Type 1 In Vitro,” Biochem. Pharmacology, 47(2), 171-174 (1994.
Krenitsky et al., “An Enzymatic Synthesis of Purine D-Arabinonucleosides,” Carbohydrate Research, 97, 139-146 (1981).
Emory Univ., Letter in re Opposition to EP 0 337 713, Aug. 22, 1997; only page one supplied.
Storer et al., “The Resolution and Absolute Stereochemistry of the Enantiomers of cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (BCH189): Equipotent Anti-HIV Agents.” Nucleosides & Nucleotides, 12(2), 225-236 (1993).
Schinazi et al. (VII), “Substrate Specificity ofEscherichia coliThymidine Phosphorylase for Pyrimidine Nucleosides with Anti-Human Immunodeficiency Virus Activity,” Biochemical Pharmacology, 44(2), 199-204 (1992).
Lin et al., “Antiviral Activity of 2′,3′-Dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-Dideoxy-β-L-cytidine (β-L-ddC) Against Hepatitis B Virus and Human Immunodeficiency Virus Type 1 In Vitro,”Biochemical Pharmacology, 47(2), 171-174 (1994).
Database WPI, Week 8748, Derwent Publications Ltd., London, GB; AN 87-338135 for JP 62-242624 A to Asahi Glass Oct. 23, 1987; [98-338135], Abstract.
Abobo et al., “Pharmacokinetics of 2′,3′-Dideoxy-5-fluoro-3′-thiacytidine in Rats,”J. Pharmaceutical Sciences, 83(1), 96-99 (Jan. 1994).
Van Aerschot et al., “3′-Fluoro-2′,c'-dideoxy-5-chlorouridine: Most Selective Anti-HIV-1 Agent among a Series of New 2′- and 3′-Fluorinated 2′,3′-Fluorinated 2′,3′-Dideoxynucleoside Analogs,”J. Med. Chem., 32(8)1743-1749 (1989).
Van Aerschot et al., “Synthesis and Anti-HIV Evaluation of 2′,3′-Dideoxy-5-chloropyrimidine Analogues: Reduced Toxicity of 5-Chlorinated 2′, 3′-Dideoxynucleosides”,J. Med. Chem., 33(6), 1833-1839 (1990).
Agrofoglio et al., “Synthesis of Carbocyclic Nucleosides,”Tetrahedron,50(36):10611-10670 (1994).
Ajmera, S., et al., “Synthesis and Biological Activity of 5-Fluoro-2′,3′-Dideoxy-3′-fluorouridine and its 5′-phosphate,”J. Med. Chem., 27(1): 11-14 (1984).
Asseline et al., “Synthesis and physiochemical properties of oligonucleotides built with either .alpha.-L or .beta.-L nucleotides units and covalently linked to an acridine derivative,”Nucl. Acids Res., 19(15):4067-4074 (1991).
Balzarini et al., “2′,3′-Didehydro-2′,3′-dideoxy-5-chlorocytidine Is A Selective Anti-Retrovirus Agent,” Bichem. Biophys. Res. Comm., 164(3), 1190-1197 (Nov. 15, 1989).
Balzarini et al., “5-Chloro-substituted Derivatives of 2′, 3′-Didehydro-2′, 3′-dideoxyuridine, 3-Fluoro-2′, 3′-dideoxyuridine and 3′-Azido-2′, 3′-dideoxyuridine as Anti-HIV Agents,”Biochem. Pharmacology, 38(6), 869-874 (1989).
Bal
Liotta Dennis C.
Schinazi Raymond F.
Crane L. E.
Emory University
King & Spalding
LandOfFree
[5-carboxamido or 5-fluoro]-[2′,3′-unsaturated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3985892